A higher dose of the experimental pill for sickle cell disease showed more promise, Fulcrum said at the American Society of ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required ...

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

A publicly funded consortium of University of California (UC) researchers and clinicians is one big step closer to realizing a decade-long plan to launch a CRISPR-based gene-editing trial for sickle ...

About 100,000 people in the U.S. have sickle cell disease, a condition that primarily affects people of color, the CDC says.

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up When Dr. Ambroise Wonkam walked into a panel on medical genetics ...

Massachusetts Institute of Technology professor Vernon Ingram, whose landmark discovery on the cause of sickle cell anemia made him a pioneer in the field of molecular biology, died in Boston on Aug.

ROANOKE, Va. – September is National Sickle Cell Awareness Month and Carillion Clinic Sickle Cell Collaborative is holding an awareness walk this weekend to honor patients and their caregivers. In ...